L&C Bio Co., Ltd
290650.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.39T
Close$
$-26574.21
139.8% downside
Current Fair Value
139.8% downsideOvervalued by 139.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.39 Trillion |
|---|---|
| Enterprise Value | $1.42 Trillion |
| Dividend Yield | $50.00 (0.09%) |
| Earnings per Share | $-5811.4 |
| Beta | 1.36 |
| Outstanding Shares | 26,970,000 |
Return
| Return on Equity | -46.04% |
|---|---|
| Return on Assets | -31.32% |
| Return on Invested Capital | 2.36% |
Valuation & Multiples
| P/E Ratio | -9.14 |
|---|---|
| PEG | -8.72 |
| Price to Sales | 15.49 |
| Price to Book Ratio | 5.37 |
| Enterprise Value to Revenue | 12.17 |
| Enterprise Value to EBIT | 172.71 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$136.30
Average shareholder expectationRevenue Estimate
$38.25 B
Average shareholder expectationNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
$-187.91
Average shareholder expectationRevenue Estimate
$42.10 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About L&C Bio Co., Ltd
155 employees
CEO: Chul Lee Whan Specializing in regenerative tissue medicine, L&C BIO Co., Ltd. operates as a dedicated research and development enterprise. The company's diverse product range encompasses human tissue products, various medical devices, and a selection ...